The Future of Global Drug Safety

Recent controversies over the safety of approved drugs such as rosiglitazone, rofecoxib, and the bisphosphonates have created the critical need for sound analysis of accumulating data on drug safety. Unfortunately, there is currently no organized way to collect data on patient adverse events on drugs and transmit risk information to physicians and patients. Instead, analyses appear in the literature that can easily be attacked on methodology and produce nothing more than anxiety on the part of patients.

This talk will show early signals that indicate that the Internet and patient communities together will use software provided by insurance companies and doctor groups to continuously advise patients on safety based on their own characteristics.